Obesity is common among people who have had cancer, and cancer treatment moves weight in both directions. A 2026 narrative review looks at what is known about using GLP-1 medicines in that group, and its most useful contribution is a warning rather than a result [1].
The warning is about cachexia. In cancer care, unintended weight loss is a symptom that gets investigated, not an outcome that gets celebrated. The review asks providers to weigh the potential negative effect of these drugs in patients with cancer cachexia or sarcopenic obesity, and in patients on anticancer therapy that already causes weight loss. A medicine whose main action is appetite suppression is not obviously benign in someone already losing weight for a reason nobody wants — the muscle side of that question is covered in how much of it is muscle.
What the review does not do is rule the drugs out. It reports that GLP-1 medicines may contribute to weight loss in survivors, with outcomes varying by cancer stage and by the type of anticancer therapy, and it describes the current literature as limited and largely retrospective. That is a call for oncology input, not a prohibition, and treating it as either extreme would misread it.
There is no pooled estimate here and no trial arm. That is worth stating plainly on a site that ranks sellers on numbers: this is a review of what has been observed, and the honest summary is that the evidence base for survivors is thin, which is also true of people who have had a kidney transplant.
The buying question follows from that. This desk ranks sellers by published price, and price is most of what they publish — the pattern counted in sellers publishing two prices and in what nobody says about a higher dose. An intake form built to sell a monthly plan is not built to ask whether someone finished chemotherapy last year.
So the advice is short and it is not about price. Anyone who has been treated for cancer should raise a GLP-1 with their oncology team before a telehealth form, because the one effect these drugs reliably produce is the one that needs interpreting differently in that context. The flat or rising question can wait.